Diligence memo · auto-generated · as of July 2, 2026

Response Biomedical Corp

Response Biomedical Corp looks fair against its niche peers and is dormant on financing cadence.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

Response Biomedical Corp operates in Biotechnology, based in VANCOUVER.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Response Biomedical Corp has raised $20M in disclosed capital across 6 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).

Largest single filing: $7.7M on 2010-07-28.

Most recent recorded round closed around 2013-09-26.

Valuation (modeled)modeled

Provath models Response Biomedical Corp at approximately $113M (range $3.4M–$613M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Fair. Modeled value is 0.71× the median modeled value of Series A Biotechnology companies in 2013–2015 (111 peers) — value vs value, same stage and era. Within the normal band (71% of peer median) for its niche.

Financing rhythm & timingmixed

Historic cadence: a new round about every 105 months.

Last raise 12.8 yr ago; this sector typically re-raises about every 14 months.

Silent for over 3× the sector's normal cadence.

The last round was 1.6× smaller than the prior — a bridge or down round.

Comparablesmixed

Capital scale ranks ahead of 68% of Biotechnology peers (4293 compared).

Modeled value ranks above 61% of those peers.

Closest niche peers: Dnanexus, Inc., Foresight Biotherapeutics, Inc., AuraSense Therapeutics, LLC, Zyomyx Inc, Champions Oncology, Inc..

Peoplefiled

24 named people on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.